NZ225426A - Anti-arrhythmic pharmaceutical compositions, in unit dosage form, containing 4-amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl)quinoline - Google Patents
Anti-arrhythmic pharmaceutical compositions, in unit dosage form, containing 4-amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl)quinolineInfo
- Publication number
- NZ225426A NZ225426A NZ225426A NZ22542688A NZ225426A NZ 225426 A NZ225426 A NZ 225426A NZ 225426 A NZ225426 A NZ 225426A NZ 22542688 A NZ22542688 A NZ 22542688A NZ 225426 A NZ225426 A NZ 225426A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- salt
- cardiac arrhythmias
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 239000002552 dosage form Substances 0.000 title claims description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 title description 3
- 239000003416 antiarrhythmic agent Substances 0.000 title description 2
- ANZIISNSHPKVRV-UHFFFAOYSA-N abanoquil Chemical compound C1=C(OC)C(OC)=CC2=NC(N3CCC=4C=C(C(=CC=4C3)OC)OC)=CC(N)=C21 ANZIISNSHPKVRV-UHFFFAOYSA-N 0.000 title 1
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims description 47
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 15
- 238000001990 intravenous administration Methods 0.000 claims description 14
- 241000282472 Canis lupus familiaris Species 0.000 claims description 11
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 5
- 229960002274 atenolol Drugs 0.000 claims description 5
- 238000002474 experimental method Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002876 beta blocker Substances 0.000 claims description 4
- 229960003712 propranolol Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 3
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 claims description 3
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 claims 1
- 229940001468 citrate Drugs 0.000 claims 1
- 229940050411 fumarate Drugs 0.000 claims 1
- 229940001447 lactate Drugs 0.000 claims 1
- 239000005555 hypertensive agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 10
- 239000002253 acid Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 4
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003248 quinolines Chemical class 0.000 description 3
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001435 haemodynamic effect Effects 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229950000405 decamethonium Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000036584 pressor response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- HLXQFVXURMXRPU-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dibromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C HLXQFVXURMXRPU-UHFFFAOYSA-L 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878716972A GB8716972D0 (en) | 1987-07-17 | 1987-07-17 | Treatment of cardiac arrhythmias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ225426A true NZ225426A (en) | 1991-03-26 |
Family
ID=10620869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ225426A NZ225426A (en) | 1987-07-17 | 1988-07-15 | Anti-arrhythmic pharmaceutical compositions, in unit dosage form, containing 4-amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl)quinoline |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0303357B1 (OSRAM) |
| JP (1) | JPS6440425A (OSRAM) |
| KR (1) | KR930001105B1 (OSRAM) |
| CN (1) | CN1019545B (OSRAM) |
| AT (1) | ATE72976T1 (OSRAM) |
| AU (1) | AU604554B2 (OSRAM) |
| CA (1) | CA1330947C (OSRAM) |
| DD (1) | DD283931A5 (OSRAM) |
| DE (1) | DE3868772D1 (OSRAM) |
| DK (1) | DK398088A (OSRAM) |
| GB (1) | GB8716972D0 (OSRAM) |
| HU (1) | HU201244B (OSRAM) |
| IE (1) | IE60356B1 (OSRAM) |
| IL (1) | IL87082A0 (OSRAM) |
| MX (1) | MX12192A (OSRAM) |
| MY (1) | MY103537A (OSRAM) |
| NZ (1) | NZ225426A (OSRAM) |
| PH (1) | PH25873A (OSRAM) |
| PT (1) | PT88002B (OSRAM) |
| YU (1) | YU137888A (OSRAM) |
| ZA (1) | ZA885092B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015204A2 (en) * | 1998-09-10 | 2000-03-23 | Aventis Pharma Deutschland Gmbh | Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| CN1328263C (zh) * | 2004-11-01 | 2007-07-25 | 上海汇伦生命科技有限公司 | 四氢异喹啉衍生物、其制备方法及药物组合物 |
| WO2015018797A2 (en) * | 2013-08-05 | 2015-02-12 | Haplogen Gmbh | Antiviral compounds |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656174A (en) * | 1982-07-24 | 1987-04-07 | Pfizer Inc. | Quinoline therapeutic agents |
-
1987
- 1987-07-17 GB GB878716972A patent/GB8716972D0/en active Pending
-
1988
- 1988-07-07 MX MX1219288A patent/MX12192A/es unknown
- 1988-07-12 MY MYPI88000771A patent/MY103537A/en unknown
- 1988-07-12 IL IL87082A patent/IL87082A0/xx not_active IP Right Cessation
- 1988-07-13 DE DE8888306378T patent/DE3868772D1/de not_active Expired - Lifetime
- 1988-07-13 AT AT88306378T patent/ATE72976T1/de active
- 1988-07-13 EP EP88306378A patent/EP0303357B1/en not_active Expired - Lifetime
- 1988-07-14 PH PH37222A patent/PH25873A/en unknown
- 1988-07-14 ZA ZA885092A patent/ZA885092B/xx unknown
- 1988-07-15 DK DK398088A patent/DK398088A/da not_active Application Discontinuation
- 1988-07-15 PT PT88002A patent/PT88002B/pt not_active IP Right Cessation
- 1988-07-15 CA CA000572131A patent/CA1330947C/en not_active Expired - Fee Related
- 1988-07-15 YU YU137888A patent/YU137888A/sh unknown
- 1988-07-15 AU AU19110/88A patent/AU604554B2/en not_active Ceased
- 1988-07-15 NZ NZ225426A patent/NZ225426A/en unknown
- 1988-07-15 IE IE217288A patent/IE60356B1/en not_active IP Right Cessation
- 1988-07-15 HU HU883711A patent/HU201244B/hu not_active IP Right Cessation
- 1988-07-15 DD DD88317993A patent/DD283931A5/de not_active IP Right Cessation
- 1988-07-15 KR KR1019880008820A patent/KR930001105B1/ko not_active Expired - Fee Related
- 1988-07-16 CN CN88104442A patent/CN1019545B/zh not_active Expired
- 1988-07-18 JP JP63178904A patent/JPS6440425A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| PT88002B (pt) | 1995-03-01 |
| EP0303357A3 (en) | 1990-08-16 |
| PH25873A (en) | 1991-12-02 |
| HUT47218A (en) | 1989-02-28 |
| AU604554B2 (en) | 1990-12-20 |
| CN1019545B (zh) | 1992-12-23 |
| ATE72976T1 (de) | 1992-03-15 |
| IL87082A0 (en) | 1988-12-30 |
| DK398088D0 (da) | 1988-07-15 |
| YU137888A (sh) | 1995-03-27 |
| PT88002A (pt) | 1989-06-30 |
| HU201244B (en) | 1990-10-28 |
| MX12192A (es) | 1993-08-01 |
| JPH0576925B2 (OSRAM) | 1993-10-25 |
| CA1330947C (en) | 1994-07-26 |
| IE882172L (en) | 1989-01-17 |
| CN1030871A (zh) | 1989-02-08 |
| IE60356B1 (en) | 1994-06-29 |
| DE3868772D1 (de) | 1992-04-09 |
| KR930001105B1 (ko) | 1993-02-18 |
| GB8716972D0 (en) | 1987-08-26 |
| ZA885092B (en) | 1990-02-28 |
| DK398088A (da) | 1989-01-18 |
| EP0303357A2 (en) | 1989-02-15 |
| AU1911088A (en) | 1989-01-19 |
| JPS6440425A (en) | 1989-02-10 |
| EP0303357B1 (en) | 1992-03-04 |
| DD283931A5 (de) | 1990-10-31 |
| KR890001552A (ko) | 1989-03-27 |
| MY103537A (en) | 1993-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MacCarthy et al. | Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects | |
| JP3221611B2 (ja) | 物質乱用障害の治療用医薬組成物 | |
| Ahmed et al. | Relationship between anti‐acetylcholine and anti‐tremorine activity in anti‐parkinsonian and related drugs | |
| JP2006213736A (ja) | 鎮痛剤およびその使用 | |
| BG64972B1 (bg) | Средство с антидепресивно действие | |
| EP1358177B1 (en) | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | |
| HU219482B (hu) | (+)Doxazoszin alkalmazása vizeletfolyást fokozó gyógyászati készítmények előállítására | |
| KR20010032009A (ko) | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 | |
| CZ285633B6 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
| EP0303357B1 (en) | 4-Amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl)quinoline for (treatment of cardiac arrhythmias). | |
| EP1099446B1 (en) | Combination for treating depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent | |
| HU190355B (en) | Process for producing pharmaceutical compositions for treating coronaria-diseases and hypertonia | |
| AU2006252211A1 (en) | New association of a sinus node If current inhibitor and a calcium inhibitor, and pharmaceutical compositions containing it | |
| TAYLOR et al. | Propylbutyldopamine: Mechanism of blood pressure lowering in hypertensive patients | |
| JP4525964B2 (ja) | 肺高血圧症予防治療剤 | |
| JPH0564124B2 (OSRAM) | ||
| US4585794A (en) | Method for treating renal insufficiency | |
| Abrahams et al. | The depletion of monoamines blocks the sympathoinhibitory response to cocaine | |
| Finch et al. | Cardiovascular withdrawal effects of clonidine and tiamenidine on abrupt cessation of oral treatment in conscious cats | |
| US4388320A (en) | 3-Aminopropoxyaryl derivative in the treatment of tremor | |
| JPS6144816A (ja) | 組み合わせ生成物およびその調製方法 | |
| JPS6379831A (ja) | １，４−ジビドロピリジン誘導体およびアシル化１，２，３，４−テトラヒドロイソキノリン−３−カルボン酸を含有する医薬組成物 | |
| Forsberg et al. | Cardiovascular effects of zimelidine and tricyclic antidepressants in conscious rats | |
| JP2003504396A (ja) | マクロライド化合物の新規用途 | |
| HU206612B (en) | Process for producing antihypertenzive combinative composition |